Skip to content
The People's CodeSearch
Menu
1 bill would change this sectionSee them

21 U.S.C. § 384e · 21, 384e of the Federal Food, Drug, and Cosmetic Act § 809

§ 384e. Recognition of foreign government inspections

1 bill would change thisH.R. 10857

(a) Inspection The Secretary—

1 bill would change thisH.R. 10857

(1) may enter into arrangements and agreements with a foreign government or an agency of a foreign government to recognize the inspection of foreign establishments registered under section 360(i) of this title in order to facilitate preapproval or risk-based inspections in accordance with the schedule established in paragraph (2) or (3) of section 360(h) of this title;

(2) may enter into arrangements and agreements with a foreign government or an agency of a foreign government under this section only with a foreign government or an agency of a foreign government that the Secretary has determined as having the capability of conducting inspections that meet the applicable requirements of this chapter; and

(3) shall perform such reviews and audits of drug safety programs, systems, and standards of a foreign government or agency for the foreign government as the Secretary deems necessary to determine that the foreign government or agency of the foreign government is capable of conducting inspections that meet the applicable requirements of this chapter.

(b) Results of inspection The results of inspections performed by a foreign government or an agency of a foreign government under this section may be used as—

(2) for any other purposes as determined appropriate by the Secretary.

(c) Periodic review

(1) In general Beginning not later than 1 year after December 29, 2022, the Secretary shall periodically assess whether additional arrangements and agreements with a foreign government or an agency of a foreign government, as allowed under this section, are appropriate.

(2) Reports to Congress Beginning not later than 4 years after December 29, 2022, and every 4 years thereafter, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report describing the findings and conclusions of each review conducted under paragraph (1).

1 bill would change thisH.R. 10857
Where this text comes from

The public laws () that wrote and changed it, and where each is printed in the Statutes at Large ().

(June 25, 1938, ch. 675, § 809, as added Pub. L. 112–144, title VII, § 712, July 9, 2012, 126 Stat. 1072; amended Pub. L. 114–255, div. A, title III, § 3101(a)(2)(X), Dec. 13, 2016, 130 Stat. 1156; Pub. L. 115–52, title VII, § 701(b), Aug. 18, 2017, 131 Stat. 1055; Pub. L. 117–328, div. FF, title III, § 3613(c), Dec. 29, 2022, 136 Stat. 5872.)

Notes (1)

Editorial Notes

Amendments

2022—Subsec. (a)(1). Pub. L. 117–328, § 3613(c)(1), inserted “preapproval or” before “risk-based inspections”.

Subsec. (c). Pub. L. 117–328, § 3613(c)(2), added subsec. (c).

2017—Subsec. (a)(1). Pub. L. 115–52 substituted “paragraph (2) or (3) of section 360(h)” for “section 360(h)(3)”.

2016—Subsec. (a)(2). Pub. L. 114–255 substituted “conducting” for “conduction”.

Would change this section

  • H.R. 10857

    Faster Clinical Trials Act

    In committee ·

Versions

Each is an official edition of the Code (a ), up to date through the named.

  • Through Public Law 119-138, Current